Drotrecogin alfa (activated) in severe sepsis
Brophy J, Costa V
Record ID 32007000443
French
Authors' objectives:
This report evaluated the efficacy, safety and cost-effectiveness of drotrecogin alfa based on the most contemporary literature.
Authors' recommendations:
In view of the uncertain clinical benefit, the evidence of increased risk of serious bleeding, and its high acquisition costs, the TAU recommends that drotrecogin alfa should not be used routinely in adult patients with severe sepsis at the MUHC and CHUM. The totality of the evidence suggests that the current MUHC/CHUM policies of restricting use of this medication to those severe sepsis patients at highest risk, is most appropriate. The current clinical measures to assure optimum drug utilization should be continued. TAU also concluded that there are no current pediatric indications for drotrecogin alfa.
As with all TAU recommendations, they will be reviewed as new evidence becomes available.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
http://www.mcgill.ca/files/tau/Final_report_Drotrecogin_alfa.pdf
Year Published:
2007
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Sepsis
Contact
Organisation Name:
Technology Assessment Unit of the McGill University Health Centre (MUHC)
Contact Address:
Technology Assessment Unit of the MUHC, Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, 5252 boul. de Maisonneuve, Bureau 3F.50, Montreal, Quebec H4A 3S5
Contact Name:
nandini.dendukuri@mcgill.ca
Contact Email:
nandini.dendukuri@mcgill.ca
Copyright:
Technology Assessment Unit of the McGill University Health Centre (MUHC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.